Company name
Molecular Partners AG
Company profile
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. MP develops targeted radiopharmaceuticals (incl. MP0712, lead Radio-DARPin candidate for SCLC in Phase 1/2a) and next-generation immune cell engagers for cancer patients. Founded in 2004, MP has offices in Zurich, Switzerland and Concord, MA, USA.
Date, time and room information
Tuesday, May 5, 12:45 - 13:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Extending the Boundaries of Targeted Cancer Therapies
Speaker information
| Name | Position | Institution |
|---|---|---|
| Laura Jeanbart | Head of Portfolio Management & Communications | Molecular Partners |
